Patents by Inventor Hung-Jyun Huang

Hung-Jyun Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC PYRAZOLE DERIVATIVES AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20220289759
    Abstract: A compound, which can act as inhibitors of protein kinases, especially Class III RTKs such as FLT3, PDGFR?, c-KIT and/or CSF-1R kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a binder of a Proteolysis-Targeting Chimera (PROTAC) thereof. The compound can be used in the treatments of diseases or conditions mediated by FLT3, PDGFR, c-KIT, and/or CSF-1R kinases, or mediated by a mutant kinase of FLT3, PDGFR, c-KIT, and/or CSF-1R kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.
    Type: Application
    Filed: August 22, 2020
    Publication date: September 15, 2022
    Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Shao-Zheng PENG, Chu-Bin LIAO, Hung-Jyun HUANG, Yuan-Ting CHO, Yi-Mei CHANG, Yu-Chih PAN
  • Quinoxaline compounds as type III receptor tyrosine kinase inhibitors
    Patent number: 10689362
    Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: June 23, 2020
    Assignee: Development Center for Biotechnology
    Inventors: Shao-Zheng Peng, Chu-Bin Liao, Hung-Kai Chen, Chen-Hsuan Ho, Hung-Jyun Huang, Shian-Yi Chiou
  • QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20190308949
    Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.
    Type: Application
    Filed: October 9, 2017
    Publication date: October 10, 2019
    Applicant: Development Center for Biotechnology
    Inventors: Shao-Zheng Peng, Chu-Bin Liao, Hung-Kai Chen, Chen-Hsuan Ho, Hung-Jyun Huang, Shian-Yi Chiou